HyQvia is a maintenance therapy for CIDP that may offer your adult patients dosing and site of care choices

AE=adverse event; AR=adverse reaction; CIDP=chronic inflammatory demyelinating polyneuropathy; HCP=healthcare professional; INCAT=Inflammatory Neuropathy Cause and Treatment; IVIG=intravenous immune globulin; MITT=modified intent to treat.

*ADVANCE-1 was a Phase III, prospective, randomized, double-blind, multicenter, placebo-controlled study in which adults with CIDP on a stable dose of IVIG for ≥12 weeks before screening were randomized to be switched to HyQvia (n=62) or placebo (n=70). Median duration of exposure was 5.3 months in the HyQvia group and 4.7 months in the placebo group.¹

^≈ADVANCE-3 was a Phase IIIb, single-arm, open-label, multicenter, extension study which assessed the long-term safety and tolerability of HyQvia for maintenance therapy for CIDP. At interim analysis, data included 79 patients with a range of follow-ups from 0 to 5.1 years.¹

^†Relapse was defined as an increase of ≥1 point relative to the pre-subcutaneous treatment baseline score in 2 consecutive adjusted INCAT disability scores obtained <7 days apart. MITT data set (N=122) analysis set.¹

^‡Patients can receive HyQvia treatment at an infusion center, in hospital or at home. It can be given by an HCP, self-administered after appropriate training or given by a trained caregiver. A choice of home administration must be a joint decision between HCP and patient; patients cannot make this decision themselves.¹ Formulary status varies by plan and may be subject to change. Depending on a patient’s medical and prescription drug benefit, prior authorization (PA) submission may be required before a patient can receive treatment with HyQvia.

^‖Infusion time median (range): 116.5 (65, 259) minutes.²

^#Causally related ARs and/or temporally associated ARs occurring within 72 hours.¹

^¶In ADVANCE-1, a total of 4 patients (3.0%) experienced ARs that led to discontinuation from the study; 3 patients in the HyQvia group and 1 in the placebo group. The ARs leading to discontinuation in the 3 HyQvia patients included: a cerebrovascular accident in 1 patient (with underlying cardiovascular risk factors), infusion site edema and infusion site pain in another patient, and nausea and chills in the third patient.¹

^§In ADVANCE-3 a total of 3 patients (3.8%) experienced ARs that led to discontinuation from the study and 1 patient (1.3%) died prior to the time of the interim analysis. The ARs leading to discontinuation in the 3 patients included: mantle cell lymphoma in one patient, muscular weakness and worsening of CIDP in another patient, and abdominal pain in the third patient. The cause of death in the 1 patient was cholangiocarcinoma.¹